Pricing Log in Create free account
Friday 6 November 2026 Export LEGN’s income statement to Excel — free account

Legend Biotech Corporation Sponsored ADR

LEGN Healthcare Biotechnology

Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.

Revenue
+51.9%
EPS
+126.1%
Free cash flow
−26.8%
Total debt
−49.6%

Quarter to June 2026, against a year earlier

23.45 0.91 +4.04%
Market cap
$4.4B
P/E
0.0×
Fwd P/E
−2,029×
Dividend yield
—
F-score
3/9
Altman Z
4.54
Beneish M
−2.08
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.57
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 1 — — 2 — — 2 — —
Insider Ownership 1.15%

Capital & Financial Ratios $m

Size
Market Cap 4,370.00
Revenue ttm 1,271.40
Net income ttm (56.20)
Free cash flow ttm (121.80)
Net debt Q (808.20)
Valuation
P/E 0.00
Forward P/E (2,029.00) (negative: loss-making)
Price / sales 3.45
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.57
Financial health
Current ratio Q 3.04 (at or above 1.5: strong)
Debt / equity Q 0.13 (at or below 0.5: strong)
Interest coverage Q (3.08)
Growth
Revenue growth Q +51.90% (above 0%: growing)
Operating income growth Q +142.85% (above 0%: growing)
EPS, this year +94.69% (at or above 15%: strong)
EPS, next year A +1,357.95% (at or above 15%: strong)
Revenue, next year A +39.76% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 42.2×; over the ten years it ranged from 2.2× in 2026 to 92.1× in 2023.
P/S against its own 10 years 8.17%
10-year low 10-year high
P/B against its own 10 years 7.95%
10-year low 10-year high
EV/Sales against its own 10 years 7.55%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,309 1,123 949 965
Receivables 100 6 13 —
Inventory 19 24 32 42
Other — — — —
1,498 1,284 1,247 1,227
2023 2024 2025 Q'26
Payables 31 39 83 77
ST’ Debt — — 319 156
Other 53 47 12 2
216 278 636 404

Compound Annual Growth %

10y 5y 3y
Sales — 65.93% 106.41%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 29.02% 10.42%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate 0.12 Actual 0.09

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 −0.13 −0.11 Beat by 0.02
Dec 2025 −0.17 −0.08 Beat by 0.09
Mar 2026 −0.02 −0.15 Miss by 0.13
Jun 2026 0.12 0.09 Miss by 0.03
Sep 2026 0.01 — Reports 11 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.29) 0.17 — — —
’25 (0.55) (0.68) (0.21) (0.16) (1.61)
’24 (0.33) — (0.68) 0.14 (0.97)
’23 (0.68) (1.14) (0.34) — (2.94)
’22 (0.27) (1.25) (0.52) — (2.81)
’21 (0.61) (0.66) (0.86) (0.74) (2.87)
’20 (0.44) (1.25) (0.50) (0.37) (2.57)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 305 388 — — —
’25 195 255 272 306 1,029
’24 94 — 160 187 627
’23 36 73 96 — 285
’22 42 12 27 — 117
’21 14 22 17 15 69
’20 14 13 13 42 82
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (85) (21) — — —
’25 (104) (13) 29 (12) (100)
’24 16 (2) (76) (82) (144)
’23 (139) (98) (298) — (393)
’22 (79) — (152) — (201)
’21 (27) (58) (45) (70) (198)
’20 (46) (57) (64) (56) (223)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (93) (28) — — —
’25 (106) (22) 24 (25) (129)
’24 9 (5) (78) (84) (158)
’23 (143) (104) (314) — (416)
’22 (91) — (152) — (224)
’21 (44) (58) (45) (115) (244)
’20 (61) (57) (64) (106) (273)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 24 63 64 82 69 117 285 627 1,029 1,271 +60.3% 1,438 1,775 1,995 +24.7%
Gross margin, % — 0.00 100.00 100.00 100.00 100.00 44.14 49.42 62.60 60.34 56.58 +60.3 pt
EBT — 14 (2) (130) (308) (407) (446) (520) (158) (283) (56) n/m
EBT margin, % — 58.65 (2.56) (202.47) (376.09) (591.63) (380.94) (182.41) (25.20) (27.47) (4.42) (86.1) pt
Net income — 0 (2) (130) (308) (407) (446) (520) (158) (283) (56) n/m
Per share, $
Per share, $ Revenue — 0.15 0.63 0.64 0.69 0.49 0.74 1.62 3.43 5.58 6.80 +57.1%
Earnings — 0.04 (0.03) (1.33) (2.57) (2.87) (2.81) (2.94) (0.97) (1.61) (0.50) n/m
Cash flow — (0.02) 3.08 (0.83) (1.89) (1.41) (1.27) (2.23) (0.79) (0.54) (0.48) +56.5%
Capex — 0.00 (0.21) (0.39) (0.42) (0.32) (0.14) (0.13) (0.08) (0.16) (0.17) n/m
Free cash flow — (0.02) 2.87 (1.22) (2.31) (1.73) (1.41) (2.36) (0.86) (0.70) (0.65) +61.5%
Book value — 0.08 0.09 (1.23) 2.37 5.44 4.68 7.11 5.69 5.44 6.58 +70.4%
Shares, m — 157 100 100 118 141 159 176 183 184 185 +2.0%
Valuation, ×
Valuation, × P/E — 1.43 3.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.5
P/S — 0.00 0.00 56.44 40.68 95.39 81.88 46.04 11.08 3.89 3.45 37.3
P/B — 0.00 0.00 0.00 11.87 8.57 10.59 8.57 5.72 4.00 3.57 5.5
EV/Sales — 0.00 0.00 55.04 34.53 84.31 73.94 41.64 9.56 3.45 2.95 33.6
EV/FCF — 0.00 0.00 (16.48) (8.25) (17.76) (15.17) (13.39) (32.34) (27.43) (30.63) (14.5)
Cash, $m
Cash, $m Operating cash flow — (2) 308 (83) (223) (198) (201) (393) (144) (100) (89) +59.6%
Capex — (1) (21) (39) (50) (45) (22) (23) (14) (29) (32) +54.4%
Free cash flow — (2) 287 (122) (273) (244) (224) (416) (158) (129) (122) +64.7%
Balance, $m
Balance, $m Working capital — 179 168 79 432 721 801 1,281 1,006 611 824 +16.6%
Net debt — (2) (211) (153) (502) (762) (762) (1,028) (821) (629) (808) +105.2%
Shareholders’ equity — 12 9 (123) 280 766 744 1,251 1,041 1,002 1,230 +73.9%
Returns, %
Returns, % ROA — 2.80 (1.30) (37.10) (60.17) (43.86) (36.43) (32.60) (10.06) (17.44) (5.32) (20.2) pt
ROIC — 0.00 0.00 0.00 0.00 (7,010.37) 0.00 (115.31) (56.37) (50.54) (9.54) (50.5) pt
ROE — 89.19 (26.96) 232.83 (385.65) (77.15) (59.11) (51.94) (15.45) (29.06) (8.08) (118.3) pt
People
People Employees — — — 650 882 1,071 1,390 1,800 2,609 2,965 — +28.8%
Revenue/emp, $m — 0.00 0.00 0.10 0.09 0.06 0.08 0.16 0.24 0.35 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Legend Biotech Corporation Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
COGT Cogent Biosciences, Inc. $5.1B — (loss-making) — (loss-making) −69.41% (below 0%: shrinking) n/m −42.01% (below 0%: shrinking) 0.00% 0.00% Compare
CRSP CRISPR Therapeutics AG $4.7B — (loss-making) — (loss-making) +1,325.08% (above 0%: growing) n/m −6.36% (below 0%: shrinking) 100.00% (1,026.48%) Compare
TVTX Travere Therapeutics, Inc. $4.7B — (loss-making) — (loss-making) +36.22% (above 0%: growing) n/m +6,379.75% (above 0%: growing) 98.72% (30.33%) Compare
DNTH Dianthus Therapeutics, Inc. $4.6B — (loss-making) — (loss-making) +205.56% (above 0%: growing) n/m −65.91% (below 0%: shrinking) 100.00% (4,832.40%) Compare
ERAS Erasca, Inc. $4.6B — (loss-making) — — n/m −4.67% (below 0%: shrinking) 0.00% 0.00% Compare
LEGN Legend Biotech Corporation Sponsored ADR $4.4B — (loss-making) — (loss-making) +51.90% (above 0%: growing) n/m −26.79% (below 0%: shrinking) 64.54% 14.37%
EWTX Edgewise Therapeutics, Inc. $4.2B 4.9× — — n/m −30.24% (below 0%: shrinking) 0.00% 0.00% Compare
DFTX Definium Therapeutics, Inc. $4.1B — (loss-making) — — n/m −78.31% (below 0%: shrinking) 0.00% 0.00% Compare
RLAY Relay Therapeutics, Inc. $3.7B — (loss-making) — (loss-making) −95.44% (below 0%: shrinking) n/m +2.13% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $4.6B — — +36.22% — −18.30% 49.36% 0.00%

All 621 Biotechnology stocks →

Legend Biotech Corporation Sponsored ADR (LEGN) Latest News

29 Oct

Impact 4 · · Zacks

28 Oct

Impact 4 · · Simply Wall St.

27 Oct

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

20 Oct

Impact 3 · · Investing.com

15 Oct

Impact 4 · · GlobeNewswire

4 Oct

Impact 3 · · Simply Wall St.

2 Oct

Impact 4 · · MT Newswires

1 Oct

Impact 3 · · GlobeNewswire

25 Sep

Impact 4 · · GlobeNewswire
Impact 4 ·

15 Sep

Impact 4 · · Stocktwits
Impact 3 ·
Impact 3 · · wsj.com

10 Sep

Impact 3 ·

11 Aug

Impact 4 · · The Motley Fool transcript
Impact 4 · transcript
Impact 4 ·
Impact 3 · · InvestorsHub
Impact 3 · · MarketBeat transcript

29 Jul

Impact 4 ·
Impact 3 ·
Impact 3 ·

27 Jul

Impact 4 · · Stocktwits
Impact 4 · · biopharmadive.com
Impact 3 ·

25 Jun

Impact 4 · · Insider Monkey

22 Jun

Impact 4 · · Insider Monkey

17 Jun

Impact 4 ·
Impact 3 ·

LEGN metrics, ten years each

stockrow.com/LEGN · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com